BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
FDA continues evaluation of nebulizer for BX004 injections in cystic fibrosis. Clinical hold on Phase 2b trial due to device data requests. DMC recommends continuation of study with adjusted dosing after safety review. Cash is sufficient to fund operations into early 2026; topline results expected then. PHGE shares down 7.18%, nearing 52-week low of $4.65.
View signal analysis